Tuesday, 27 February 2024


J&J to invest $3.9 M in Singapore R&D

14 March 2018 | News

The winning applications sought to pursue novel approaches in the areas of eye health, cancer and liver disease.

A Division of J&J (China) Investment Ltd., Johnson & Johnson (J&J) Innovation  has announced the three finalists that will receive S$5.1 million (~$3.9 million) in support of research projects for up to three years through the J&J Innovation World Without Disease Grant Call Collaboration with Singapore’s Agency for Science, Technology, and Research (A*STAR). 

The grant call was aimed at advancing the discovery and development of solutions to prevent, intercept and cure diseases. J&J Innovation and A*STAR selected the three research projects from more than 40 highly-qualified applicants from Singapore’s public sector. The winning applications sought to pursue novel approaches in the areas of eye health, cancer and liver disease. 

A team from the Singapore Eye Research Institute (SERI) will study light and outdoor patterns for the prevention of myopia; a joint team from the Singapore Immunology Network, the p53 Laboratory, the National University of Singapore and the National Cancer Centre Singapore will study a novel antibody with the potential to benefit the several millions of people living with cancer; and a team consisting of researchers from the the Genome Institute of Singapore and National University Health System will conduct a program for the early detection of non-alcoholic fatty liver disease (NAFLD), allowing timely disease interception and the potential to reverse liver damage. 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account